Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 8,218 Shares

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 8,218 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $66.02, for a total value of $542,552.36. Following the sale, the chief executive officer now directly owns 376,742 shares of the company’s stock, valued at $24,872,506.84. This represents a 2.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

William Lewis also recently made the following trade(s):

• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Performance

NASDAQ:INSM opened at $65.25 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The firm has a market cap of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The business has a 50 day moving average price of $71.23 and a 200-day moving average price of $72.42.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same period in the prior year, the firm earned ($1.10) earnings per share. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. Equities research analysts predict that Insmed Incorporated will post -5.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on INSM shares. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. Truist Financial reissued a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America lifted their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Institutional Trading of Insmed

Several large investors have recently modified their holdings of the business. V Square Quantitative Management LLC bought a new position in Insmed during the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC increased its stake in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the period. Exchange Traded Concepts LLC raised its holdings in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. Blue Trust Inc. lifted its stake in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 1,879 shares during the period. Finally, JCIC Asset Management Inc. bought a new stake in Insmed in the third quarter valued at $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.